Insider trade

Gilead Sciences (GILD)CEO sold ~$17.3M

Daniel Patrick O'day, CEO at Gilead Sciences, sold ~$17.3M of Gilead Sciences shares.

~$17.3M
Approx. value · 116K sh @ $150.00: 614K
Holds after · shares reported

Traded: Feb 5, 2026
Filed: Feb 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Dec 12, 2025Government · Federal Register noticeDetermination That DEMEROL (Meperidine Hydrochloride) Tablet, 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Dec 15, 2025Insider · 2 peopleInsiders: 2 sales (~$732K)
Dec 29, 2025InsiderCEO sold ~$1.25M of GILD shares in the open market
Jan 15, 2026Insider · 2 peopleInsiders: 2 sales (~$746K)
Jan 20, 2026InsiderDirector sold ~$618K of GILD shares in the open market
Jan 21, 2026Layoff notice · 4010 Ocean Ranch Blvd Oceanside CA 92056Layoff notice filed in CA: 34 employees
Jan 23, 2026InsiderCEO sold ~$15.6M of GILD shares in the open market
Jan 27, 2026CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
Jan 28, 2026Insider · 1 personInsiders: 2 sales (~$1.4M)
Feb 5, 2026 · this disclosureInsiderCEO sold ~$17.3M of GILD shares in the open market

What came next

Feb 5, 20265% stakeFMR LLC reported a passive stake (13G) of 5.3%
Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
Feb 17, 2026Insider · 2 peopleInsiders: 4 sales (~$4.8M)
Feb 22, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
Feb 27, 2026Insider · 1 personInsiders: 3 sales (~$1.4M)
Mar 16, 2026Insider · 2 peopleInsiders: 2 sales (~$865K)
Mar 25, 2026Layoff notice · 333 Lakeside Drive San Mateo CA 94404Layoff notice filed in CA: 51 employees
Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
Mar 27, 2026InsiderCEO sold ~$1.37M of GILD shares in the open market
Apr 15, 2026Insider · 2 peopleInsiders: 2 sales (~$846K)
Apr 28, 2026Insider · 1 personInsiders: 2 sales (~$1.3M)
Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
Apr 30, 2026Layoff notice · 800 Bridge Parkway Redwood City CA 94065Layoff notice filed in CA: 108 employees
May 7, 2026Company filing · Form 8-K · ResultsReported its results
May 14, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
May 15, 2026Insider · 2 peopleInsiders: 5 sales (~$4.1M)
May 22, 2026FDAFDA drug approval: Hepcludex
May 22, 2026Government · Federal Register noticeNotice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
Jun 1, 2026Insider · 1 personInsiders: 3 sales (~$2.0M)

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Gilead Sciences

For Gilead Sciences, OQRO holds 28 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 78 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.

Other recent filings by Daniel Patrick O'day, Chairman & CEO

The full history of Daniel Patrick O'day, Chairman & CEO is on the profile page.

How this filing works

Other disclosures at Gilead Sciences

Everything OQRO holds on this company is on its GILD page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data